Virios therapeutics completes enrollment of 425 patients in phase 2b “fortress” clinical trial for fibromyalgia

Atlanta--(business wire)---- $viri #biotech--virios therapeutics, inc. (nasdaq: viri), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that it has completed enrollment in its phase 2b fortress (fibromyalgia outcome research trial evaluating synergistic suppression of herpes simplex virus-1 (“hsv-1”)) study, which is a randomized, double-blind evaluation of imc-1 in patients with fi
VIRI Ratings Summary
VIRI Quant Ranking